Special Issue "Biomarkers in Chronic Kidney Disease"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Therapeutic Strategies in Different Diseases".

Deadline for manuscript submissions: 31 October 2020.

Special Issue Editors

Prof. Dr. Francisco Herrera-Gómez
Website
Guest Editor
Pharmacological Big Data Laboratory, Faculty of Medicine, University of Valladolid, Valladolid, Spain
Interests: pharmacoepidemiology; pharmacometrics; pharmaceutical regulatory sciences; biopharmaceuticals; nanopharmaceuticals
Prof. Dr. F. Javier Álvarez
Website
Guest Editor
Pharmacology, Faculty of Medicine, University of Valladolid, Valladolid, Spain
Interests: pharmacoepidemiology; pharmacometrics; pharmaceutical regulatory sciences; biopharmaceuticals; nanopharmaceuticals

Special Issue Information

Dear Colleagues,

In the evaluation of the real impact of medicines along the wide spectrum of chronic kidney disease (CKD), authentic treatment-effect modifiers, i.e., markers of the effect of medicines, and independent prognostic factors, i.e., markers of the likely progress of a disease regardless of the treatment given, are urgently needed in order to personalize therapies in this population. Also known as a predictive biomarker, the status of treatment effect modifiers changes in accordance with the effect of a given medicine, so it may be used to discern between good and poor responders. Prognostic biomarkers do not change but allow identifying those patients with a better (or worse) prognosis. Importantly, overall information on biomarkers for patients into the kidney disease-improving global outcomes (KDIGO) glomerular filtration rate (GFR) categories G3a to G5 is scarce: Potential markers present a paradoxical effect, mostly evident among end-stage kidney disease (ESKD) patients, compared to individuals with normal kidney function (NKF) or patients in early stages of CKD (KDIGO GFR categories G1 to G2). This Special Issue on Biomarkers in Chronic Kidney Disease is thus aimed as a compilation of original research articles and review articles on potential candidates to predictive and prognostic biomarkers in this susceptible population.

Prof. Dr. Francisco Herrera-Gómez
Prof. Dr. F. Javier Álvarez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • chronic kidney disease
  • end-stage kidney disease
  • susceptible population
  • treatment-effect modifiers
  • prognosis
  • personalized medicine
  • translational medicine
  • humans

Published Papers

This special issue is now open for submission.
Back to TopTop